Press Releases – Sigilon Therapeutics, Inc.

Year

Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer,

Apr 8, 2021

PDF Version

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full

Mar 18, 2021

PDF Version

Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and Drug

Mar 5, 2021

PDF Version

Sigilon Therapeutics to Present at Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer,

Mar 4, 2021

PDF Version

Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™

Results demonstrate potential of Company’s therapies developed using its novel Shielded Living Therapeutics™ platform to treat broad range of chronic diseases CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional

Feb 8, 2021

PDF Version

Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer,

Jan 13, 2021

PDF Version